Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is a clinical-stage biopharmaceutical company that focuses on developing a broad pipeline of novel biologic therapeutic candidates targeting oncology and rare diseases. With its proprietary modular protein engineering platforms, Inhibrx aims to create therapeutic candidates that address complex disease biology effectively. The company’s leading candidates include INBRX-109 and INBRX-106, which utilize multivalent formats to optimize agonist functions for specific targets.
One of the notable projects is INBRX-101, a recombinant human AAT-Fc fusion protein designed to treat patients with Alpha-1 Antitrypsin Deficiency (AATD). The ElevAATe trial, a randomized, controlled, double-blind, head-to-head superiority study, is currently evaluating INBRX-101 against plasma-derived AAT therapies. The trial aims to achieve sustained therapeutic levels with a less frequent dosing interval, addressing the limitations of current weekly infusions required by existing treatments. Initial results are anticipated by late 2024.
In another strategic move, Inhibrx has secured global rights for INBRX-101, as Chiesi Farmaceutici S.p.A declined the option for ex-North American rights, promising broader strategic opportunities in launching treatments for conditions like Graft versus Host Disease (GvHD) in markets such as Europe and Japan.
Additionally, the company has shown promising results in their Phase 1 trial of INBRX-109 combined with chemotherapies for advanced Ewing sarcoma, indicating a disease control rate of 76.9% among evaluated patients, with the majority achieving partial responses or stable disease.
Financially, Inhibrx is on the verge of a significant transaction with Sanofi, which involves the sale of INBRX-101 assets while spinning off its remaining pipeline into a new publicly traded entity, Inhibrx Biosciences, Inc. This move will position Inhibrx to continue advancing its other clinical programs and leverage its strong pipeline for future developments.
For more detailed information, visit their official website at www.inhibrx.com.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the CTOS 2021 Virtual Annual Meeting from November 10-13, 2021. The company will present findings on its drug candidate, INBRX-109, focused on conventional chondrosarcoma and Ewing sarcoma. Presentations include an oral update on safety and efficacy on November 11, and a poster detailing cohort expansion plans. Inhibrx will also participate in multiple upcoming investor conferences in November and December. These presentations are expected to bolster investor confidence and showcase advancements in their oncology pipeline.
On October 28, 2021, Inhibrx (Nasdaq: INBX) announced the appointment of three key executives: David Matly as Chief Commercial Officer, David Kao as Vice President of Regulatory Affairs, and Jack Tsai as Vice President of Business Development. These strategic hires aim to enhance the company's clinical pipeline focused on areas with high unmet medical need, such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma. Additionally, Kristiina Vuori joined the Board of Directors, taking over from Brendan Eckelman, who stepped down but continues to lead research strategy.
Inhibrx, Inc. (Nasdaq: INBX) announced interim results from a Phase 1 clinical trial for INBRX-101, a recombinant human AAT-Fc fusion protein aimed at treating alpha-1 antitrypsin deficiency (AATD). The study involved 21 patients with no severe adverse events reported, and only mild to moderate drug-related effects. Dose-dependent increases in AAT levels were observed, with promising results indicating the potential for monthly dosing compared to the current standard of care requiring 52 infusions annually. Further data from multiple ascending doses is expected in early 2022.
Inhibrx, Inc. (Nasdaq: INBX) will host a live webcast on October 12, 2021, at 5:30 a.m. PT to present interim results from its Phase 1 clinical trial of INBRX-101, a treatment for alpha-1 antitrypsin deficiency (AATD). AATD affects approximately 100,000 patients in the U.S. and leads to severe lung function loss. INBRX-101 is designed for monthly dosing, addressing shortcomings of current weekly plasma-derived treatments. Further details and results will be available on Inhibrx's website following the presentation.
Inhibrx, a clinical-stage biotechnology company (NASDAQ: INBX), announced its participation in the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. Pacific Time. This virtual presentation will showcase its novel biologic therapeutic candidates in oncology and orphan diseases, utilizing its proprietary sdAb platform. Attendees can access the live webcast through Inhibrx's investor website, which will remain available for 60 days post-event. The company collaborates with major biotech firms, enhancing its research capabilities.
Inhibrx, Inc. (Nasdaq: INBX) reported its financial results for Q2 2021, showing cash and cash equivalents of $125.7 million, a slight decrease from $128.7 million at year-end 2020. R&D expenses decreased to $17.9 million, down from $19.0 million in Q2 2020, while G&A expenses rose to $2.9 million from $1.5 million. The company recorded a net loss of $20.7 million ($0.55 per share), compared to a net loss of $17.9 million ($0.99 per share) in the same quarter last year. The financial report reflects ongoing development in its clinical programs.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a potential registration-enabling Phase 2 study of INBRX-109 for chondrosarcoma, an orphan bone cancer with no approved treatments. The drug has shown promising results in an ongoing Phase 1 trial with disease control in 87.5% of patients. An additional loan agreement with Oxford Finance was amended, providing $40M in capital. The FDA granted Fast Track designation to INBRX-109 in January 2021. The new Phase 2 trial aims to evaluate the drug's efficacy through progression-free survival metrics.
Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology firm, will present at two upcoming virtual investor conferences: the Jefferies Healthcare Conference on June 2 at 12:30 p.m. PT and the JMP Securities Life Sciences Conference on June 17 at 8:00 a.m. PT. Live webcasts of these presentations can be accessed through the investor section of Inhibrx's website and will remain available for 60 days post-event. The company focuses on developing biologic therapeutic candidates for oncology and orphan diseases, utilizing advanced protein engineering techniques.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q1 2021 financial results on May 13, 2021. The company had cash and cash equivalents of $108 million, a decrease from $128.7 million at the end of 2020. R&D expenses dropped to $16.4 million, while G&A expenses rose to $3 million due to increased personnel costs. The net loss for the quarter was $19.3 million or $0.51 per share, an improvement from $20.1 million or $1.11 per share in Q1 2020. Inhibrx is progressing with its four clinical programs and expects data from all by year-end.
Inhibrx, Inc. (Nasdaq: INBX) announced its fourth quarter and fiscal year 2020 financial results, highlighting a transformative year with advancements in four clinical programs. The Phase 1 study of INBRX-105 showed a maximum tolerated dose of 1 mg/kg, with 44% of evaluable patients achieving stable disease. Cash and cash equivalents grew significantly to $128.7 million at year-end. However, the company reported a net loss of $76.1 million for the fiscal year, worsening from a net loss of $51.4 million in 2019.
FAQ
What is the current stock price of Inhibrx Biosciences (INBX)?
What is the market cap of Inhibrx Biosciences (INBX)?
What is Inhibrx Biosciences, Inc.?
What are the main therapeutic candidates of Inhibrx?
What is INBRX-101?
What is the ElevAATe trial?
What were the results of the Phase 1 trial for INBRX-109?
What is the significance of Chiesi declining the option for INBRX-101?
What is the financial condition of Inhibrx?
What is the significance of the acquisition by Sanofi?
Will Inhibrx continue as a publicly traded company?